De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Artivion Beheer

Beheer criteriumcontroles 4/4

De CEO Artivion's is Pat Mackin, benoemd in Sep2014, heeft een ambtstermijn van 10.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.18M, bestaande uit 24.4% salaris en 75.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.59% van de aandelen van het bedrijf, ter waarde $ 17.73M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 8 jaar.

Belangrijke informatie

Pat Mackin

Algemeen directeur

US$3.2m

Totale compensatie

Percentage CEO-salaris	24.4%
Dienstverband CEO	10.1yrs
Eigendom CEO	1.6%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jun 27

Analyse CEO-vergoeding

Hoe is Pat Mackin's beloning veranderd ten opzichte van Artivion's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$3m	US$776k	-US$31m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$7m	US$750k	-US$19m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$5m	US$728k	-US$15m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$3m	US$606k	-US$17m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$6m	US$689k	US$2m
Sep 30 2019	n/a	n/a	US$2m
Jun 30 2019	n/a	n/a	US$3m
Mar 31 2019	n/a	n/a	US$709k
Dec 31 2018	US$3m	US$660k	-US$3m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$3m	US$640k	US$4m

Compensatie versus markt: De totale vergoeding ($USD 3.18M ) Pat } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).

Compensatie versus inkomsten: De vergoeding van Pat is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pat Mackin (57 yo)

10.1yrs

Tenure

US$3,176,413

Compensatie

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Mackin	Chairman	10.1yrs	US$3.18m	1.59% $ 17.6m
Lance Berry	Executive VP of Finance	less than a year	US$1.64m	0.19% $ 2.1m
Amy Horton	VP & Chief Accounting Officer	18.2yrs	US$1.06m	0.33% $ 3.7m
Jean Holloway	Senior VP	9.5yrs	US$993.72k	0.39% $ 4.3m
John Davis	Senior VP & Chief Commercial Officer	less than a year	US$953.41k	0.38% $ 4.2m
Matthew Getz	VP of Human Resources & Chief Human Resources Officer	5.2yrs	geen gegevens	0.081% $ 902.1k
Marshall Stanton	Senior VP of Clinical Research & Chief Medical Officer	3.6yrs	US$1.61m	0.20% $ 2.2m
Robert Thomson	Vice President of Research & Development	1.3yrs	geen gegevens	0.032% $ 351.5k
Florian Tyrs	Vice President of Global Operations	4.3yrs	geen gegevens	0.061% $ 679.2k

4.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AORT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Mackin	Chairman	10yrs	US$3.18m	1.59% $ 17.6m
James Bullock	Independent Director	8yrs	US$217.50k	0.15% $ 1.6m
Thomas Ackerman	Independent Director	20.8yrs	US$230.00k	0.34% $ 3.8m
Anthony Semedo	Independent Director	3yrs	US$217.50k	0.082% $ 903.2k
Daniel Bevevino	Independent Director	20.8yrs	US$235.00k	0.34% $ 3.8m
Jeffrey Burbank	Independent Presiding Director	7.1yrs	US$265.00k	0.11% $ 1.3m
Jon Salveson	Independent Director	12.4yrs	US$215.00k	0.29% $ 3.3m
Marna Borgstrom	Independent Director	6.3yrs	US$220.00k	0.10% $ 1.1m
Elizabeth Hoff	Independent Director	2yrs	US$210.00k	0.060% $ 662.7k

8.0yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AORT wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

Artivion Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

VP & Chief Accounting Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director recently sold US$243k worth of stock

Independent Director notifies of intention to sell stock

Artivion, Inc., Annual General Meeting, May 14, 2024

Chairman recently sold US$262k worth of stock

Recent updates

VP & Chief Accounting Officer notifies of intention to sell stock

Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Insider notifies of intention to sell stock

Independent Director recently sold US$243k worth of stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS exceeds analyst expectations

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 9.2% to US$27.47

Price target increased by 9.2% to US$27.47

Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Is Artivion (NYSE:AORT) Using Too Much Debt?

Senior VP notifies of intention to sell stock

Artivion Stock: A First Assessment

VP & Chief Accounting Officer notifies of intention to sell stock

Artivion, Inc. Announces Chief Financial Officer Changes

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Consensus EPS estimates fall by 29%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Senior Vice President of Operations recently sold US$248k worth of stock

Price target increased by 10% to US$24.90

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Chairman recently sold US$293k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Insider exercised options to buy US$115k worth of stock.

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Price target decreased to US$23.13

Price target decreased to US$23.13

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)

Artivion, Inc. Provides Revenue Guidance for the Year 2022

Artivion, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Artivion, Inc. Announces the Appointment of Elizabeth A. Hoff to Board of Directors

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Price target decreased to US$26.96

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial